Login to Your Account

Lexicon's Sanofi-backed diabetes candidate hits endpoint in phase III

By Michael Fitzhugh
Staff Writer

Friday, September 9, 2016

Top-line results showing that type 1 diabetics treated with the dual SGLT inhibitor sotagliflozin achieved statistically significant reductions in A1C at 24 weeks in a pivotal phase III trial drew fresh enthusiasm for Lexicon Pharmaceuticals Inc. Friday.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription